Longitudinal Imaging Biomarkers of Disease Progression in DLB

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Kejal Kantarci
Study ID
NCT03582488
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

  • Lewy Body Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 18F-Flortaucipir — DRUG
    Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology

Study Details

The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.

Key Dates

Start date
Jun 25, 2018
Status verified
Mar 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
135 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Dementia with Lewy Bodies
    18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology

Primary Outcome Measure

Rate of change in 18F-Flortaucipir PET imaging and Pittsburgh compound-B PET imaging [ Time Frame: Will be assessed 3 times annually over at least three years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo ClinicJacksonvilleFlorida32224-
Mayo ClinicRochesterMinnesota55905-

Find similar trials in Jacksonville, FL

By research site
Mayo Clinic· Jacksonville, FLMayo Clinic· Rochester, MN

Related Studies